Other Briefings
India’s Trade Performance in FY 2025-26: Moderate Export Growth Amid Shifting Trade Dynamics
India’s total exports hit US$860.09 billion in FY 2025-26, led by a 7.94 percent surge in services. Explore the full breakdown of merchandise trends and key growth drivers amid global geopolitical shifts.
Honey Harvest 2026: Why the World is Looking to India to Fill the “Honey Gap”
India has extended the natural honey MEP to US$1,400/MT until Dec 31, 2026. Learn how India’s honey industry is scaling global exports, improving producer price transmission, and capturing new opportunities in a disrupted international market.
How the India-EU FTA Opens New Doors for Swedish Businesses in India
Learn how the India–EU FTA 2026 is reshaping India–Sweden trade, AI partnerships, and investment opportunities in high-tech and sustainable industries.
India’s FDI Policy for Border-Country (LBC) Investors: Implications for China-Linked Capital
Assess whether your China-linked investment qualifies under India’s new FDI rules. Understand ownership thresholds, risks, and structuring options.
Indian Commercial Landscape for Austrian (and Styrian) Companies: Where the Opportunities Lie
Explore India–Austria trade trends, investment flows, and high-potential sectors for Austrian firms, with insights for market entry and expansion in India.
New Compliance Rules for Exporters: DGFT Mandates Digital Certificate of Origin
India’s export compliance framework is undergoing a significant shift as the DGFT mandates fully digital issuance and stricter oversight of the Certificate of Origin (CoO). The amendments to FTP and HBP 2023 streamline verification and reinforce regulatory oversight.
India’s Mandatory Halal Certification 2026: New Country List & I-CAS Compliance Deadlines
India has expanded the I-CAS Halal certification requirement to 20 additional markets, bringing the total number of covered export destinations to 35 as of 2026. Explore the newly added markets and implementation timelines for exporters.
US Pharma Tariff 2026: Decoding the 100% Patented Drug Levy and the Generic Exemption
The US administration under President Donald J. Trump has implemented a 100% tariff on patented pharma products to curb import dependence. While Indian generics are exempt for now, a one-year review and API onshoring rules signal long-term shifts.
